HOME > Publication & Reports > Annual Report 2021 > Hospital

Annual Report 2021

Department of Diagnostic Pathology

Yasushi Yatabe, Shigeki Sekine, Nobuyoshi Hiraoka, Noriko Motoi, Akiko Maeshima, Taisuke Mori, Hirokazu Taniguchi, Masayuki Yoshida, Akihiko Yoshida, Hiroshi Yoshida, Kaishi Satomi, Taiki Hashimoto, Tomoaki Naka, Yuuki Nishimura, Junpei Yonemaru, Takeshi Ushikusa, Naoki Kojima, Nobuyasu Ikai, Natsumi Terada, Nami Yamamoto, Yuuka Takahashi, Sachiko Miura, Chizu Kina, Toshiko Sakaguchi, Shoichi Harada, Yuka Izumi, Aoi Miyata, Gulanbar Amori, Sachiyo Hasegawa, Yuko Kashiwazaki, Nozomi Handa, Takaaki Shiina, Kimii Shiba, Yukihiro Takeuchi

Introduction

The Department of Diagnostic Pathology is responsible for histological and cytological diagnoses and autopsies in the National Cancer Center Hospital. In 2019, the department consisted of 12 staff pathologists, 7 residents, and 14 pathology technologists, including 12 cytotechnologists. We accepted a total of 25,502 histological specimens, including 20,806 biopsy and 4,696 surgically resected specimens and 12,731 cytological specimens (Table 1). These included 1,969 intraoperative frozen sections and 342 intraoperative cytological diagnoses. We also provided a total of 192 pathological diagnoses for the outpatient clinic via the pathology consultation system.

The Team and What We Do

Accurate and precise histological and cytological diagnoses play a key role in cancer treatment performed in the hospital. The basis for this is gross observation and conventional hematoxylin-eosin staining of specimens, but we also actively perform immunohistochemistry and special stain retrieval. In recent years, the detection of genetic abnormalities and expression of particular molecules has become more important in clinical practice, because several of the alterations were used to select the patients for molecular targeted therapy, treatment using immune checkpoint inhibitors and prediction of clinical outcomes. Although the number of pathological autopsies has remained stable over the past few years, the evaluation of the cause of death, the biological basis of the diseases and therapeutic effects in the autopsy specimens is indispensable to contribute to and improve the quality of medical care of our hospital. This year, 21,424 biopsy and surgical specimens, 10,838 cytological diagnoses, and 14 autopsies were obtained (Table 1). We consider that connection to the clinical departments is very important. Thus, joint conferences are held regularly, in addition to regular intradepartmental conferences and autopsy reviews.

We also encourage research work, which are studies for improving pathology diagnostics, clarifying biological features of diseases, and providing helpful findings for selecting therapeutic options.

Table 1. Number of specimens diagnosed in 2020

Research activities

Our department covers a wide range of research in pathology from basic to clinical aspects, which are conducted by the individual organ-based units, led by Drs. N. Hiraoka (hepatobiliary and pancreatic malignancies), A. Maeshima (hematology) , T. Mori (head and neck malignancies), K. Satomi (brain tumors), S. Sekine (gastrointestinal tract), Y. Yatabe (thoracic malignancies), A. Yoshida (bone and soft tissue malignancies), H. Yoshida (gynecology) and M. Yoshida (breast malignancies).

Education

We have actively accepted pathology residents and clinical fellows for pathology training and have produced many pathologists across the country. With the introduction of the specialist system, we have been operating a training program for board certification as a core institution. At present, one senior resident, six residents and three trainees for board certification are enrolled in the department.

Future Prospects

Our goal is to accomplish comprehensive pathological diagnosis, which is closely related to clinical practice, with the highest priority on medical safety. We also attempt to train pathologists who are in short supply in Japan and provide training in pathology for tumor diagnosis. It is also important for us to develop research activities in cooperation with clinical departments and laboratories, and to apply biological abnormalities in tumors to diagnoses.

List of papers published in 2021

Journal

1. Cheung CC, Smith AC, Albadine R, Bigras G, Bojarski A, Couture C, Cutz JC, Huang WY, Ionescu D, Itani D, Izevbaye I, Karsan A, Kelly MM, Knoll J, Kwan K, Nasr MR, Qing G, Rashid-Kolvear F, Sekhon HS, Spatz A, Stockley T, Tran-Thanh D, Tucker T, Waghray R, Wang H, Xu Z, Yatabe Y, Torlakovic EE, Tsao MS. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. Lung Cancer 2021; 160: 127-135. https://doi.org/10.1016/j.lungcan.2021.08.003

2. Hamada A, Soh J, Hata A, Nakamatsu K, Shimokawa M, Yatabe Y, Oizumi H, Tsuboi M, Horinouchi H, Yoshino I, Tanahashi M, Toyooka S, Okada M, Yokomise H, Yamashita M, Nishimura Y, Yamamoto N, Nakagawa K, Mitsudomi T. Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clin Lung Cancer 2021; 22: 596-600. https://doi.org/10.1016/j.cllc.2021.04.006

3. Hasegawa Y, Tsukahara K, Yoshimoto S, Miura K, Yokoyama J, Hirano S, Uemura H, Sugasawa M, Yoshizaki T, Homma A, Chikamatsu K, Suzuki M, Shiotani A, Matsuzuka T, Kohno N, Miyazaki M, Oze I, Matsuo K, Kosuda S, Yatabe Y. Reply to P. Kaul et al. J Clin Oncol 2021; 39: 3518-3519. https://doi.org/10.1200/JCO.21.01554

4. Hasegawa Y, Tsukahara K, Yoshimoto S, Miura K, Yokoyama J, Hirano S, Uemura H, Sugasawa M, Yoshizaki T, Homma A, Chikamatsu K, Suzuki M, Shiotani A, Matsuzuka T, Kohno N, Miyazaki M, Oze I, Matsuo K, Kosuda S, Yatabe Y, Group HR. Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial. J Clin Oncol 2021; 39: 2025-2036. https://doi.org/10.1200/JCO.20.03637

5. Ikegami M, Kohsaka S, Hirose T, Ueno T, Inoue S, Kanomata N, Yamauchi H, Mori T, Sekine S, Inamoto Y, Yatabe Y, Kobayashi H, Tanaka S, Mano H. MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples. Commun Biol 2021; 4: 1396. https://doi.org/10.1038/s42003-021-02930-4

6. Ishizu K, Hashimoto T, Naka T, Yatabe Y, Kojima M, Kuwata T, Nonaka S, Oda I, Esaki M, Kudo M, Gotohda N, Yoshida T, Yoshikawa T, Sekine S. APC mutations are common in adenomas but infrequent in adenocarcinomas of the non-ampullary duodenum. J Gastroenterol 2021; 56: 988-998. https://doi.org/10.1007/s00535-021-01823-x

7. Karigane D, Kasahara H, Shiroshita K, Fujita S, Kobayashi H, Tamaki S, Yamazaki R, Yahagi K, Yatabe Y, Kondoh N, Arai T, Katagiri H, Shimizu N, Sakurai M, Kikuchi T, Kato J, Shimizu T, Hayakawa T, Yaguchi T, Matsushita M, Nakajima H, Kawakami Y, Murata M, Mori T, Sasaki T, Okamoto S, Takubo K. Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph(+) B cells but not bone marrow stem/progenitors. Leuk Lymphoma 2021; 62: 679-687. https://doi.org/10.1080/10428194.2020.1837366

8. Kobayashi K, Yoshimoto S, Ando M, Matsumoto F, Murakami N, Omura G, Honma Y, Matsumoto Y, Ikeda A, Sakai A, Eguchi K, Ito A, Ryo E, Yatabe Y, Mori T. Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence. Oral Oncol 2021; 113: 105091. https://doi.org/10.1016/j.oraloncology.2020.105091

9. Kuroda H, Masago K, Takahashi Y, Fujita S, Sasaki E, Nakada T, Sakakura N, Nakanishi H, Matsushita H, Yatabe Y. Positive Correlation Between the Number of Circulating Tumor Cells in the Pulmonary Vein and Tumor Spread Through Air Spaces in Resected Non-small Cell Lung Cancer. Anticancer Res 2021; 41: 5499-5505. https://doi.org/10.21873/anticanres.15363

10. Matsui T, Sakakura N, Koyama S, Nakanishi K, Sasaki E, Kato S, Hosoda W, Murakami Y, Kuroda H, Yatabe Y. Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma. Ann Thorac Surg 2021; 112: 1118-1126. https://doi.org/10.1016/j.athoracsur.2020.09.042

11. Mino-Kenudson M, Le Stang N, Daigneault JB, Nicholson AG, Cooper WA, Roden AC, Moreira AL, Thunnissen E, Papotti M, Pelosi G, Motoi N, Poleri C, Brambilla E, Redman M, Jain D, Dacic S, Yatabe Y, Tsao MS, Lopez-Rios F, Botling J, Chen G, Chou TY, Hirsch FR, Beasley MB, Borczuk A, Bubendorf L, Chung JH, Hwang D, Lin D, Longshore J, Noguchi M, Rekhtman N, Sholl L, Travis W, Yoshida A, Wynes MW, Wistuba, II, Kerr KM, Lantuejoul S. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. J Thorac Oncol 2021; 16: 686-696. https://doi.org/10.1016/j.jtho.2020.12.026

12. Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Jpn J Clin Oncol 2021; 51: 1757-1760. https://doi.org/10.1093/jjco/hyab159

13. Morita C, Yoshida T, Shirasawa M, Masuda K, Matsumoto Y, Shinno Y, Yagishita S, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Motoi N, Yatabe Y, Ohe Y. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep 2021; 11: 18762. https://doi.org/10.1038/s41598-021-98275-3

14. Muto Y, Ryo E, Namikawa K, Takahashi A, Ogata D, Fujimura T, Yatabe Y, Aiba S, Yamazaki N, Mori T. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma. Pathol Int 2021; 71: 337-347. https://doi.org/10.1111/pin.13090

15. Narita Y, Sasaki E, Masuishi T, Taniguchi H, Kadowaki S, Ito S, Yatabe Y, Muro K. PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer. J Gastrointest Oncol 2021; 12: 2696-2705. https://doi.org/10.21037/jgo-21-505

16. Nishimura Y, Ryo E, Yamazaki N, Yatabe Y, Mori T. Cutaneous Primary NUT Carcinoma With BRD3-NUTM1 Fusion. Am J Surg Pathol 2021; 45: 1582-1584. https://doi.org/10.1097/PAS.0000000000001801

17. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Fujiwara Y. Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. Front Oncol 2021; 11: 732525. https://doi.org/10.3389/fonc.2021.732525

18. Sakao Y, Kuroda H, Saito Y, Yamauchi Y, Yokote F, Kawamura M, Yatabe Y. Radiological imaging and pathological findings of small lung adenocarcinoma: a narrative review. J Thorac Dis 2021; 13: 366-371. https://doi.org/10.21037/jtd-20-844

19. Sakuma K, Sasaki E, Hosoda W, Komori K, Shimizu Y, Yatabe Y, Aoki M. MYB mediates downregulation of the colorectal cancer metastasis suppressor heterogeneous nuclear ribonucleoprotein L-like during epithelial-mesenchymal transition. Cancer Sci 2021; 112: 3846-3855. https://doi.org/10.1111/cas.15069

20. Satoh H, Okuma Y, Kashima J, Konnno-Yamamoto A, Yatabe Y, Ohe Y. Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma. Onco Targets Ther 2021; 14: 2911-2915. https://doi.org/10.2147/OTT.S300229

21. Shibayama T, Makise N, Motoi T, Mori T, Hiraoka N, Yonemori K, Watanabe SI, Esaki M, Morizane C, Okuma T, Kawai A, Ushiku T, Yatabe Y, Yoshida A. Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases: A Proposal of Risk Stratification and Identification of a Synaptophysin-positive Aggressive Subset. Am J Surg Pathol 2021; 45: 616-626. https://doi.org/10.1097/PAS.0000000000001660

22. Shimoda Y, Yoshida T, Shirasawa M, Mizuno T, Jo H, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y, Motoi N. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. Anticancer Res 2021; 41: 5739-5747. https://doi.org/10.21873/anticanres.15390

23. Sugawara H, Watanabe H, Kunimatsu A, Abe O, Watanabe SI, Yatabe Y, Kusumoto M. Adenocarcinoma in situ and minimally invasive adenocarcinoma in lungs of smokers: image feature differences from those in lungs of non-smokers. BMC Med Imaging 2021; 21: 172. https://doi.org/10.1186/s12880-021-00705-1

24. Sugawara S, Sone M, Itou C, Kimura S, Kusumoto M, Kato T, Yonemori K, Yatabe Y, Arai Y. Analysis of factors affecting the diagnostic yield of image-guided percutaneous core needle biopsy for peritoneal/omental lesions. Abdom Radiol (NY) 2021; 46: 4499-4508. https://doi.org/10.1007/s00261-021-03088-7

25. Sunami K, Bando H, Yatabe Y, Naito Y, Takahashi H, Tsuchihara K, Toyooka S, Mimori K, Kohsaka S, Uetake H, Kinoshita I, Komine K, Takeda M, Hayashida T, Tamura K, Nishio K, Yamamoto N, Working Group of a Joint Task Force of Three Academic Societies for the Promotion of Cancer Genomic M. Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. Cancer Sci 2021; 112: 3911-3917. https://doi.org/10.1111/cas.15022

26. Suzuki M, Yagishita S, Sugihara K, Ogitani Y, Nishikawa T, Ohuchi M, Teishikata T, Jikoh T, Yatabe Y, Yonemori K, Tamura K, Hasegawa K, Hamada A. Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Clin Cancer Res 2021; 27: 3970-3979. https://doi.org/10.1158/1078-0432.CCR-21-0397

27. Suzuki M, Matsumoto Y, Imabayashi T, Teishikata T, Tsuchida T, Asamura H, Yatabe Y. Cryobiopsy as a reliable technique for the preoperative identification of micropapillary/solid components in early-stage lung adenocarcinoma. Lung Cancer 2021; 162: 147-153. https://doi.org/10.1016/j.lungcan.2021.11.004

28. Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Kakishima H, Tsuchida T, Yamamoto N, Ohe Y, Yatabe Y. Feasibility of next-generation sequencing (Oncomine DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. Jpn J Clin Oncol 2021; 51: 1114-1122. https://doi.org/10.1093/jjco/hyab059

29. Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Kakishima H, Tsuchida T, Yamamoto N, Ohe Y, Yatabe Y. Corrigendum to: Feasibility of next-generation sequencing (Oncomine DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. Jpn J Clin Oncol 2021; 51: 1183. https://doi.org/10.1093/jjco/hyab092

30. Tanaka Y, Chiwaki F, Kojima S, Kawazu M, Komatsu M, Ueno T, Inoue S, Sekine S, Matsusaki K, Matsushita H, Boku N, Kanai Y, Yatabe Y, Sasaki H, Mano H. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer 2021; 2: 962-977. https://doi.org/10.1038/s43018-021-00240-6

31. Teishikata T, Shiraishi K, Shinno Y, Kobayashi Y, Kashima J, Ishiyama T, Yoshida T, Mori T, Yatabe Y. An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping. J Thorac Oncol 2021; 16: 2133-2138. https://doi.org/10.1016/j.jtho.2021.07.028

32. Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol 2021; 17: 4045-4055. https://doi.org/10.2217/fon-2021-0549

33. Yagishita S, Kato K, Takahashi M, Imai T, Yatabe Y, Kuwata T, Suzuki M, Ochiai A, Ohtsu A, Shimada K, Nishida T, Hamada A, Mano H. Characterization of the large-scale Japanese patient-derived xenograft (J-PDX) library. Cancer Sci 2021; 112: 2454-2466. https://doi.org/10.1111/cas.14899

34. Yatabe Y, Yoshiki Y, Matsumura K, Togo K, Kikkawa H, Iadeluca L, Li B, Nishio K. Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan. JTO Clin Res Rep 2021; 2: 100136. https://doi.org/10.1016/j.jtocrr.2020.100136

35. Yonemaru J, Hashimoto T, Takayanagi D, Naka T, Yatabe Y, Kanemitsu Y, Shiraishi K, Sekine S. NTRK fusion-positive colorectal cancer in Japanese population. Pathol Int 2021; 71: 355-359. https://doi.org/10.1111/pin.13082

36. Yoshida A, Hashimoto T, Ryo E, Yoshida KI, Motoi T, Yatabe Y, Mori T. Confirmation of NKX3-1 Expression in EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma Using Monoclonal Antibody Immunohistochemistry, RT-PCR, and RNA In Situ Hybridization. Am J Surg Pathol 2021; 45: 578-582. https://doi.org/10.1097/PAS.0000000000001627

37. Yotsukura M, Asamura H, Motoi N, Kashima J, Yoshida Y, Nakagawa K, Shiraishi K, Kohno T, Yatabe Y, Watanabe SI. Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung. J Thorac Oncol 2021; 16: 1312-1320. https://doi.org/10.1016/j.jtho.2021.04.007

38. Cho H, Hashimoto T, Naka T, Yatabe Y, Oda I, Saito Y, Yoshikawa T, Sekine S. Activating KRAS and GNAS mutations in heterotopic submucosal glands of the stomach. J Gastroenterol 2022; 57: 333-343. https://doi.org/10.1007/s00535-022-01863-x

39. Fujikawa R, Muraoka Y, Kashima J, Yoshida Y, Ito K, Watanabe H, Kusumoto M, Watanabe SI, Yatabe Y. Clinicopathologic and Genotypic Features of Lung Adenocarcinoma Characterized by the International Association for the Study of Lung Cancer Grading System. J Thorac Oncol 2022; 17: 700-707. https://doi.org/10.1016/j.jtho.2022.02.005

40. Horinouchi H, Kusumoto M, Yatabe Y, Aokage K, Watanabe SI, Ishikura S. Lung Cancer in Japan. J Thorac Oncol 2022; 17: 353-361. https://doi.org/10.1016/j.jtho.2021.11.020

41. Jain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Prince SS, Schmitt F, Yatabe Y, Eppenberger-Castori S, Bubendorf L, Committee IP. Non-small cell lung carcinoma subtyping in conventional cytology: Results of the IASLC Cytology Working Group survey to determine specific cytomorphological criteria for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol 2022. https://doi.org/10.1016/j.jtho.2022.02.013

42. Jo H, Yagishita S, Hayashi Y, Ryu S, Suzuki M, Kohsaka S, Ueno T, Matsumoto Y, Horinouchi H, Ohe Y, Watanabe SI, Motoi N, Yatabe Y, Mano H, Takahashi K, Hamada A. Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations. Mol Cancer Ther 2022; 21: 359-370. https://doi.org/10.1158/1535-7163.MCT-21-0371

43. Kawakubo N, Okubo Y, Yotsukura M, Yoshida Y, Nakagawa K, Yonemori K, Watanabe H, Yatabe Y, Watanabe SI. Assessment of Resectability of Mediastinal Germ Cell Tumor Using Preoperative Computed Tomography. J Surg Res 2022; 272: 61-68. https://doi.org/10.1016/j.jss.2021.11.002

44. Kojima N, Komiyama M, Shinoda Y, Watanabe SI, Yatabe Y, Kawai A, Yoshida A. Liposarcoma With Hibernoma-like Histology: A Clinicopathologic Study of 16 Cases. Am J Surg Pathol 2022. https://doi.org/10.1097/PAS.0000000000001911

45. Kojima N, Arai Y, Satomi K, Kubo T, Matsushita Y, Mori T, Matsushita H, Ushijima T, Yatabe Y, Shibata T, Yonemori K, Ichimura K, Ichikawa H, Kawai A, Yoshida A. Co-expression of ERG and CD31 in a subset of CIC-rearranged sarcoma: a potential diagnostic pitfall. Mod Pathol 2022. https://doi.org/10.1038/s41379-022-01078-8

46. Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 2022; 40: 201-218 e209. https://doi.org/10.1016/j.ccell.2022.01.001

47. Maekawa M, Taniguchi T, Nishio K, Sakai K, Matsushita K, Nakatani K, Ishige T, Ikejiri M, Nishihara H, Sunami K, Yatabe Y, Hatanaka KC, Hatanaka Y, Yamamoto Y, Fukuyama K, Oda S, Saito K, Yokomura M, Kubo Y, Sato H, Tanaka Y, Fuchioka M, Yamasaki T, Matsuda K, Kurachi K, Funai K, Baba S, Iwaizumi M. Precision cancer genome testing needs proficiency testing involving all stakeholders. Sci Rep 2022; 12: 1494. https://doi.org/10.1038/s41598-022-05589-x

48. Muraoka Y, Yoshida Y, Nakagawa K, Ito K, Watanabe H, Narita T, Watanabe SI, Tsukiji Lung Cancer Working G, Yotsukura M, Motoi N, Yatabe Y. Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection. J Thorac Cardiovasc Surg 2022; 163: 1656-1665 e1653. https://doi.org/10.1016/j.jtcvs.2021.06.053

49. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol 2022; 17: 362-387. https://doi.org/10.1016/j.jtho.2021.11.003

50. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Motoi N, Yatabe Y, Yoshida Y, Watanabe S, Kondo T. Establishment and characterization of NCC-DMM1-C1, a novel patient-derived cell line of desmoplastic malignant pleural mesothelioma. Oncol Lett 2022; 23: 64. https://doi.org/10.3892/ol.2021.13182

51. Okubo Y, Kashima J, Teishikata T, Muraoka Y, Yotsukura M, Yoshida Y, Nakagawa K, Watanabe H, Kusumoto M, Watanabe SI, Yatabe Y. Prognostic Impact of the Histologic Lepidic Component in Pathologic Stage IA Adenocarcinoma. J Thorac Oncol 2022; 17: 67-75. https://doi.org/10.1016/j.jtho.2021.09.006

52. Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Janne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba, II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol 2022; 33: 466-487. https://doi.org/10.1016/j.annonc.2022.02.003

53. Shibayama T, Shimoi T, Mori T, Noguchi E, Honma Y, Hijioka S, Yoshida M, Ogawa C, Yonemori K, Yatabe Y, Yoshida A. Cytokeratin-positive Malignant Tumor in the Abdomen With EWSR1/FUS-CREB Fusion: A Clinicopathologic Study of 8 Cases. Am J Surg Pathol 2022; 46: 134-146. https://doi.org/10.1097/PAS.0000000000001742

54. So C, Yoshida T, Mizuno T, Yatabe Y, Ohe Y. Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report. Thorac Cancer 2022; 13: 1423-1426. https://doi.org/10.1111/1759-7714.14392

55. Sone M, Sugawara S, Yatabe Y. Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine. Curr Oncol Rep 2022. https://doi.org/10.1007/s11912-022-01271-7

56. Sugawara H, Watanabe H, Kunimatsu A, Abe O, Yatabe Y, Watanabe SI, Kusumoto M. Tumor size in patients with severe pulmonary emphysema might be underestimated on preoperative CT. Eur Radiol 2022; 32: 163-173. https://doi.org/10.1007/s00330-021-08105-3

57. Sugawara H, Ito K, Watanabe H, Morita T, Yatabe Y, Watanabe SI, Kusumoto M. Clinical usefulness of PET/MRI in differentiating anterior mediastinal masses. Nucl Med Commun 2022; 43: 92-99. https://doi.org/10.1097/MNM.0000000000001483

58. Takemura C, Kashima J, Hashimoto T, Ichikawa H, Honma Y, Goto Y, Watanabe SI, Yatabe Y. A mimic of lung adenocarcinoma: a case report of histological conversion of metastatic thyroid papillary carcinoma. Histopathology 2022; 80: 1004-1007. https://doi.org/10.1111/his.14607

59. Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, Hase T, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba, II, Hanash S, Taguchi A. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. J Natl Cancer Inst 2022; 114: 290-301. https://doi.org/10.1093/jnci/djab183

60. Watanabe H, Fujishima F, Komoto I, Imamura M, Hijioka S, Hara K, Yatabe Y, Kudo A, Masui T, Tsuchikawa T, Sakamoto K, Shiga H, Nakamura T, Nakaya N, Motoi F, Unno M, Sasano H. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors. Cancers (Basel) 2022; 14. https://doi.org/10.3390/cancers14030775

61. Yoshida A, Arai Y, Satomi K, Kubo T, Ryo E, Matsushita Y, Hama N, Sudo K, Komiyama M, Yatabe Y, Shibata T, Ichikawa H, Ichimura K, Kawai A, Mori T. Identification of novel SSX1 fusions in synovial sarcoma. Mod Pathol 2022; 35: 228-239. https://doi.org/10.1038/s41379-021-00910-x

62. Higashiyama M, Kobayashi Y, Kashima J, Muraoka M, Watanabe H, Kusumoto M, Watanabe S, Yatabe Y. Invasive Mucinous Adenocarcinoma of the Lung with a Mural Nodule-like Lesion. Am J Surg Pathol 2022; In press:

63. Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature 603(7900):335-342. (2022)

64. Okagawa Y, Yoshinaga S, Noguchi E, Sekine S. Gastric metastasis from primary leiomyosarcoma of the broad ligament. Jpn J Clin Oncol. 2021 Apr 30;51(5):846-847. doi: 10.1093/jjco/hyab009.

65. Yonemaru J, Hashimoto T, Takayanagi D, Naka T, Yatabe Y, Kanemitsu Y, Shiraishi K, Sekine S. NTRK fusion-positive colorectal cancer in Japanese population. Pathol Int. 2021 May;71(5):355-359. doi: 10.1111/pin.13082.

66. Ueda S, Yamashita S, Watanabe SI, Wakabayashi M, Motoi N, Noguchi M, Sekine S, Sato Y, Ushijima T. Influence of degree of DNA degradation in formalin-fixed and paraffin-embedded tissue samples on accuracy of genome-wide DNA methylation analysis. Epigenomics. 2021 Apr;13(8):565-576. doi: 10.2217/epi-2020-0431.

67. Takamaru H, Saito Y, Sekiguchi M, Yamada M, Sakamoto T, Matsuda T, Sekine S, Ochiai H, Tsukamoto S, Shida D, Kanemitsu Y. Endoscopic Resection Before Surgery Does Not Affect the Recurrence Rate in Patients With High-Risk T1 Colorectal Cancer. Clin Transl Gastroenterol. 2021 Apr 12;12(4):e00336. doi: 10.14309/ctg.0000000000000336.

68. Ueno H, Kajiwara Y, Ajioka Y, Sugai T, Sekine S, Ishiguro M, Takashima A, Kanemitsu Y. Histopathological atlas of desmoplastic reaction characterization in colorectal cancer. Jpn J Clin Oncol. 2021 May 28;51(6):1004-1012. doi: 10.1093/jjco/hyab040.

69. Mizuguchi Y, Tanaka Y, Cho H, Sekiguchi M, Takamaru H, Yamada M, Sakamoto T, Matsuda T, Hashimoto T, Sekine S, Saito Y. Endoscopic features of isolated and traditional serrated adenoma-associated superficially serrated adenomas of the colorectum. Dig Endosc. 2022 Jan;34(1):153-162. doi: 10.1111/den.13992.

70. Kitamura K, Shida D, Sekine S, Ahiko Y, Nakamura Y, Moritani K, Tsukamoto S, Kanemitsu Y. Comparison of model fit and discriminatory ability of the 8th edition of the tumor-node-metastasis classification and the 9th edition of the Japanese classification to identify stage III colorectal cancer. Int J Clin Oncol. 2021 Sep;26(9):1671-1678. doi: 10.1007/s10147-021-01955-3.

71. Kasuga K, Saito Y, Takamaru H, Yamada M, Sakamoto T, Sekine S, Uraoka T. Optical real-time biopsy by endocytoscopy: a case of sessile serrated lesion with dysplasia. Endoscopy. 2022 May;54(5):E249-E251. doi: 10.1055/a-1443-4276.

72. Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama T, Ishikawa H, Nakajima T, Chino A, Shimodaira H, Hirasawa A, Nakayama Y, Sekine S, Tamura K, Akagi K, Kawasaki Y, Kobayashi H, Arai M, Itabashi M, Hashiguchi Y, Sugihara K; Japanese Society for Cancer of the Colon, Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer. Int J Clin Oncol. 2021 Aug;26(8):1353-1419. doi: 10.1007/s10147-021-01881-4.

73. Kasuga K, Yamada M, Shida D, Tagawa T, Takamaru H, Sekiguchi M, Sakamoto T, Uraoka T, Sekine S, Kanemitsu Y, Saito Y. Treatment outcomes of endoscopic submucosal dissection and surgery for colorectal neoplasms in patients with ulcerative colitis. United European Gastroenterol J. 2021 Oct;9(8):964-972. doi: 10.1002/ueg2.12118.

74. Wada T, Yoshikawa T, Sekine S, Kamiya A, Hayashi T, Otsuki S, Yamagata Y, Katai H. Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy. Eur J Surg Oncol. 2022 Feb;48(2):333-338. doi: 10.1016/j.ejso.2021.07.016.

75. Ishizu K, Hashimoto T, Naka T, Yatabe Y, Kojima M, Kuwata T, Nonaka S, Oda I, Esaki M, Kudo M, Gotohda N, Yoshida T, Yoshikawa T, Sekine S. APC mutations are common in adenomas but infrequent in adenocarcinomas of the non-ampullary duodenum. J Gastroenterol. 2021 Nov;56(11):988-998. doi: 10.1007/s00535-021-01823-x.

76. Zhang CD, Takeshima H, Sekine S, Yamashita S, Liu YY, Hattori N, Abe H, Yamashita H, Fukuda M, Imamura Y, Ushiku T, Katai H, Makino H, Watanabe M, Seto Y, Ushijima T. Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation. Gastric Cancer. 2022 Mar;25(2):336-345. doi: 10.1007/s10120-021-01252-y.

77. Tsuyuki S, Takeshima H, Sekine S, Yamagata Y, Ando T, Yamashita S, Maeda S, Yoshikawa T, Ushijima T. Comparable genetic alteration profiles between gastric cancers with current and past Helicobacter pylori infection. Sci Rep. 2021 Dec 6;11(1):23443. doi: 10.1038/s41598-021-02761-7.

78. Ikegami M, Kohsaka S, Hirose T, Ueno T, Inoue S, Kanomata N, Yamauchi H, Mori T, Sekine S, Inamoto Y, Yatabe Y, Kobayashi H, Tanaka S, Mano H. MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples. Commun Biol. 2021 Dec 15;4(1):1396. doi: 10.1038/s42003-021-02930-4.

79. Toyoshima N, Saito Y, Yamada M, Takamaru H, Sekine S, Kasuga K, Kudo SE. Early colorectal lesion (depressed type) detected using artificial intelligence. Endoscopy. 2022 Feb 4. doi: 10.1055/a-1732-7197.

80. Tanaka Y, Chiwaki F, Kojima S, Kawazu M, Komatsu M, Ueno T, Inoue S, Sekine S, Matsusaki K, Matsushita H, Boku N, Kanai Y, Yatabe Y, Sasaki H, Mano H. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer. 2021 Sep;2(9):962-977. doi: 10.1038/s43018-021-00240-6.

81. Saito Y, Ono A, García VAJ, Mizuguchi Y, Hisada I, Takamaru H, Yamada M, Sekiguchi M, Makiguchi M, Sekine S, Abe S. Diagnosis and treatment of colorectal tumors: Differences between Japan and the West and future prospects. DEN open. 2021 Nov 11;2(1):e66. doi: 10.1002/deo2.66.

82. Boottanun P, Ino Y, Shimada K, Hiraoka N, Angata K, Narimatsu H. Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma. On

83. Capodanno Y, Chen Y, Schrader J, Tomosugi M, Sumi S, Yokoyama A, Hiraoka N, Ohki R. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization. Neoplasia 2021; 23: 979-992. https://doi.org/10.1016/j.neo.2021.07.008

84. Endo Y, Fujimoto M, Ito N, Takahashi Y, Kitago M, Gotoh M, Hiraoka N, Yoshida T, Kitagawa Y, Kanai Y, Arai E. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling. J Cancer Res Clin Oncol 2021; 147: 1341-1354. https://doi.org/10.1007/s00432-021-03541-6

85. Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Itoh M, Chen WY, Takano M, Yoshikawa T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayakawa N, Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O, Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe Y, Suematsu M. Corrigendum to “On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity” [Redox Biol. 41 (2021) 101926]. Redox Biol 2021; 44: 102028. https://doi.org/10.1016/j.redox.2021.102028

86. Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Itoh M, Chen WY, Takano M, Yoshikawa T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayakawa N, Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O, Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe Y, Suematsu M. On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biol 2021; 41: 101926. https://doi.org/10.1016/j.redox.2021.101926

87. Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N, Ito Y, Katayama H, Ueno M, Ikeda M, Sugimori K, Okano N, Shimizu K, Yanagimoto H, Okusaka T, Ozaka M, Todaka A, Nakamori S, Tobimatsu K, Sata N, Kawashima Y, Hosokawa A, Yamaguchi T, Miyakawa H, Hara H, Mizuno N, Ishii H. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol 2021; 51: 235-243. https://doi.org/10.1093/jjco/hyaa198

88. Iwasaki T, Nara S, Nishimura Y, Ueda H, Kishi Y, Esaki M, Shimada K, Hiraoka N. Postoperative acute multiple organ failure after hepatectomy in a Nigerian male with sickle cell trait: a case report. Surg Case Rep 2021; 7: 19. https://doi.org/10.1186/s40792-020-01102-6

89. Oishi T, Sasaki Y, Tong Y, Chen L, Onodera T, Iwasa S, Udo E, Furusato B, Fujimori H, Imamichi S, Honda T, Bessho T, Fukuoka J, Ashizawa K, Yanagihara K, Nakao K, Yamada Y, Hiraoka N, Masutani M. A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer. Glob Health Med 2021; 3: 226-235. https://doi.org/10.35772/ghm.2021.01001

90. Onishi Y, Kusumoto M, Motoi N, Hiraoka N, Sugawara S, Itou C, Sone M. Natural History of Epithelioid Hemangioendothelioma of the Liver: CT Findings of 15 Cases. Acad Radiol 2021; 28: 778-782. https://doi.org/10.1016/j.acra.2020.04.015

91. Shibayama T, Makise N, Motoi T, Mori T, Hiraoka N, Yonemori K, Watanabe SI, Esaki M, Morizane C, Okuma T, Kawai A, Ushiku T, Yatabe Y, Yoshida A. Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases: A Proposal of Risk Stratification and Identification of a Synaptophysin-positive Aggressive Subset. Am J Surg Pathol 2021; 45: 616-626. https://doi.org/10.1097/pas.0000000000001660

92. Kitamura K, Esaki M, Sone M, Sugawara S, Hiraoka N, Nara S, Ban D, Takamoto T, Mizui T, Shimada K. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Ann Surg Oncol 2022. https://doi.org/10.1245/s10434-022-11950-1

93. Nakajima K, Ino Y, Naito C, Nara S, Shimasaki M, Ishimoto U, Iwasaki T, Doi N, Esaki M, Kishi Y, Shimada K, Hiraoka N. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Br J Cancer 2022; 126: 628-639. https://doi.org/10.1038/s41416-021-01639-9

94. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol 2022; 18: 2351-2360. https://doi.org/10.2217/fon-2022-0214

95. Okura K, Esaki M, Nara S, Ban D, Takamoto T, Shimada K, Hiraoka N. Hepatoid carcinoma and related entities of the extrahepatic bile duct: A clinicopathological study of four cases. Pathol Int 2022; 72: 332-342. https://doi.org/10.1111/pin.13226

96. Sawada J, Hiraoka N, Qi R, Jiang L, Fournier-Goss AE, Yoshida M, Kawashima H, Komatsu M. Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival. Cancer Immunol Res 2022; 10: 468-481. https://doi.org/10.1158/2326-6066.Cir-21-0369

97. Takamizawa S, Morizane C, Tanabe N, Maruki Y, Kondo S, Hijioka S, Ueno H, Sugano K, Hiraoka N, Okusaka T. Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome. J Hepatobiliary Pancreat Sci 2022; 29: 377-384. https://doi.org/10.1002/jhbp.1063

98. Ikegami M, Kohsaka S, Hirose T, Ueno T, Inoue S, Kanomata N, Yamauchi H, Mori T, Sekine S, Inamoto Y, Yatabe Y, Kobayashi H, Tanaka S, Mano H. MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples. Commun Biol 2021; 4: 1396. https://doi.org/10.1038/s42003-021-02930-4

99. Kashihara T, Nakamura S, Murakami N, Ito K, Matsumoto Y, Kobayashi K, Omura G, Mori T, Honma Y, Kubo Y, Okamoto H, Takahashi K, Inaba K, Okuma K, Igaki H, Nakayama Y, Kato K, Matsumoto F, Yoshimoto S, Itami J. Initial Experience of Intentional Internal High-Dose Policy Volumetric Modulated Arc Therapy of Neck Lymph Node Metastases ≥ 2 cm in Patients With Head and Neck Squamous Cell Carcinoma. Front Oncol 2021; 11: 651409. https://doi.org/10.3389/fonc.2021.651409

100. Kobayashi K, Yoshimoto S, Ando M, Matsumoto F, Murakami N, Omura G, Honma Y, Matsumoto Y, Ikeda A, Sakai A, Eguchi K, Ito A, Ryo E, Yatabe Y, Mori T. Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence. Oral Oncol 2021; 113: 105091. https://doi.org/10.1016/j.oraloncology.2020.105091

101. Makise N, Mori T, Motoi T, Shibahara J, Ushiku T, Yoshida A. Recurrent FOS rearrangement in proliferative fasciitis/proliferative myositis. Mod Pathol 2021; 34: 942-950. https://doi.org/10.1038/s41379-020-00725-2

102. Maruyama S, Mori T, Yamazaki M, Abé T, Ryo E, Kano H, Hasegawa G, Tanuma JI. Central mucoepidermoid carcinoma arising directly from a glandular odontogenic cyst of the mandible: a case report. Diagn Pathol 2021; 16: 61. https://doi.org/10.1186/s13000-021-01124-0

103. Meng X, Matsumoto F, Mori T, Miura N, Ino Y, Onidani K, Kobayashi K, Matsuzaki Y, Yoshimoto S, Ikeda K, Honda K. BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Anticancer Res 2021; 41: 1089-1099. https://doi.org/10.21873/anticanres.14867

104. Murakami N, Mori T, Machida R, Kodaira T, Ito Y, Shikama N, Konishi K, Matsumoto Y, Murakami Y, Nakamura N, Yamashita H, Yorozu A, Yoshimura M, Inoue K, Nozaki M, Ishikura S, Itami J, Nishimura Y, Kagami Y. Prognostic Value of Epithelial Cell Adhesion Molecules in T1-2N0M0 Glottic Cancer. Laryngoscope 2021; 131: 1522-1527. https://doi.org/10.1002/lary.29348

105. Muto Y, Ryo E, Namikawa K, Takahashi A, Ogata D, Fujimura T, Yatabe Y, Aiba S, Yamazaki N, Mori T. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma. Pathol Int 2021; 71: 337-347. https://doi.org/10.1111/pin.13090

106. Nakagawa M, Kobayashi E, Yamada M, Watanabe T, Hirata M, Tanabe N, Ushiama M, Sakamoto H, Sato C, Mori T, Yoshida A, Yoshida T, Sugano K, Kawai A. Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report. Hered Cancer Clin Pract 2021; 19: 34. https://doi.org/10.1186/s13053-021-00192-z

107. Nishimura Y, Ryo E, Yamazaki N, Yatabe Y, Mori T. Cutaneous Primary NUT Carcinoma With BRD3-NUTM1 Fusion. Am J Surg Pathol 2021; 45: 1582-1584. https://doi.org/10.1097/pas.0000000000001801

108. Onidani K, Miura N, Sugiura Y, Abe Y, Watabe Y, Kakuya T, Mori T, Yoshimoto S, Adachi J, Kiyoi T, Kabe Y, Suematsu M, Tomonaga T, Shibahara T, Honda K. Possible Therapeutic Strategy Involving the Purine Synthesis Pathway Regulated by ITK in Tongue Squamous Cell Carcinoma. Cancers (Basel) 2021; 13. https://doi.org/10.3390/cancers13133333

109. Ota Y, Noguchi T, Ariji E, Fushimi C, Fuwa N, Harada H, Hayashi T, Hayashi R, Honma Y, Miura M, Mori T, Nagatsuka H, Okura M, Ueda M, Uzawa N, Yagihara K, Yagishita H, Yamashiro M, Yanamoto S, Kirita T. General rules for clinical and pathological studies on oral cancer (2nd edition): a synopsis. Int J Clin Oncol 2021; 26: 623-635. https://doi.org/10.1007/s10147-020-01812-9

110. Shibayama T, Makise N, Motoi T, Mori T, Hiraoka N, Yonemori K, Watanabe SI, Esaki M, Morizane C, Okuma T, Kawai A, Ushiku T, Yatabe Y, Yoshida A. Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases: A Proposal of Risk Stratification and Identification of a Synaptophysin-positive Aggressive Subset. Am J Surg Pathol 2021; 45: 616-626. https://doi.org/10.1097/pas.0000000000001660

111. Takai E, Omata W, Totoki Y, Nakamura H, Shiba S, Takahashi A, Namikawa K, Mori T, Yamazaki N, Shibata T, Yachida S. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Cancer Sci 2021; 112: 4748-4757. https://doi.org/10.1111/cas.15088

112. Takamizawa S, Honma Y, Murakami N, Mori T, Oka H, Yamamoto S, Kashihara T, Ito K, Kubo Y, Ikeda A, Matsumoto F, Omura G, Kobayashi K, Itami J, Kato K, Yoshimoto S. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma. Invest New Drugs 2021; 39: 564-570. https://doi.org/10.1007/s10637-020-00999-y

113. Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, Sunami K, Kubo T, Kohno T, Akihiko Y, Yamamoto N, Yonemori K. Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. JCO Precis Oncol 2021; 5. https://doi.org/10.1200/po.20.00383

114. Teishikata T, Shiraishi K, Shinno Y, Kobayashi Y, Kashima J, Ishiyama T, Yoshida T, Mori T, Yatabe Y. An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping. J Thorac Oncol 2021; 16: 2133-2138. https://doi.org/10.1016/j.jtho.2021.07.028

115. Tsutsui K, Namikawa K, Mori T, Kato K, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. J Dermatol 2021; 48: e114-e115. https://doi.org/10.1111/1346-8138.15718

116. Yorozu T, Nagahama K, Morii T, Maeda D, Yoshida A, Mori T, Hayashi A, Shibahara J. Myoepithelioma-like Hyalinizing Epithelioid Tumor of the Foot Harboring an OGT-FOXO1 Fusion. Am J Surg Pathol 2021; 45: 287-290. https://doi.org/10.1097/pas.0000000000001539

117. Yoshida A, Hashimoto T, Ryo E, Yoshida KI, Motoi T, Yatabe Y, Mori T. Confirmation of NKX3-1 Expression in EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma Using Monoclonal Antibody Immunohistochemistry, RT-PCR, and RNA In Situ Hybridization. Am J Surg Pathol 2021; 45: 578-582. https://doi.org/10.1097/pas.0000000000001627

118. Eguchi K, Omura G, Shimoi T, Kageyama D, Igaki H, Abe Y, Watanabe T, Aihara Y, Sakai A, Matsumoto Y, Sakai T, Yonemori K, Mori T, Yoshida A, Yoshimoto S. BCOR-CCNB3 sarcoma arising in the pharynx. Auris Nasus Larynx 2022. https://doi.org/10.1016/j.anl.2022.04.012

119. Itami J, Kobayashi K, Mori T, Honma Y, Kubo Y, Murakami N, Omura G, Okuma K, Inaba K, Takahashi K, Kashihara T, Shimizu Y, Takahashi A, Nakayama Y, Matsumoto F, Yoshimoto S, Igaki H. Non-Robustness of Ang's Risk Classification in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in Japanese Patients. Cancers (Basel) 2022; 14. https://doi.org/10.3390/cancers14102442

120. Kashihara T, Igaki H, Ogata D, Nakayama H, Nakamura S, Okuma K, Mori T, Yamakawa K, Takahashi A, Namikawa K, Takahashi A, Takahashi K, Kaneda T, Inaba K, Murakami N, Nakayama Y, Okamoto H, Yamazaki N, Itami J. Prognostic factor analysis of definitive radiotherapy using intensity-modulated radiation therapy and volumetric modulated arc therapy with boluses for scalp angiosarcomas. Sci Rep 2022; 12: 4355. https://doi.org/10.1038/s41598-022-08362-2

121. Kojima N, Arai Y, Satomi K, Kubo T, Matsushita Y, Mori T, Matsushita H, Ushijima T, Yatabe Y, Shibata T, Yonemori K, Ichimura K, Ichikawa H, Kawai A, Yoshida A. Co-expression of ERG and CD31 in a subset of CIC-rearranged sarcoma: a potential diagnostic pitfall. Mod Pathol 2022. https://doi.org/10.1038/s41379-022-01078-8

122. Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 2022; 40: 201-218 e209. https://doi.org/10.1016/j.ccell.2022.01.001

123. Shibayama T, Shimoi T, Mori T, Noguchi E, Honma Y, Hijioka S, Yoshida M, Ogawa C, Yonemori K, Yatabe Y, Yoshida A. Cytokeratin-positive Malignant Tumor in the Abdomen With EWSR1/FUS-CREB Fusion: A Clinicopathologic Study of 8 Cases. Am J Surg Pathol 2022; 46: 134-146. https://doi.org/10.1097/pas.0000000000001742

124. Tsutsui K, Ogata D, Tsukamoto S, Moritani K, Mori T, Namikawa K, Takahashi A, Kanemitsu Y, Yamazaki N. Post-Immunotherapy Robotic-Assisted Resection for Primary Anorectal Melanoma: A Case Report. Case Rep Oncol 2022; 15: 56-61. https://doi.org/10.1159/000520858

125. Watanabe S, Ochiai H, Sakuma H, Mori T, Yazawa M, Oka A, Kishi K. Muscle Fiber Composition Changes after Selective Nerve Innervation. Int J Mol Sci 2022; 23. https://doi.org/10.3390/ijms23147856

126. Yoshida A, Satomi K, Kobayashi E, Ryo E, Matsushita Y, Narita Y, Ichimura K, Kawai A, Mori T. Soft-tissue sarcoma with MN1-BEND2 fusion: A case report and comparison with astroblastoma. Genes Chromosomes Cancer 2022; 61: 427-431. https://doi.org/10.1002/gcc.23028

127. Yoshida A, Arai Y, Satomi K, Kubo T, Ryo E, Matsushita Y, Hama N, Sudo K, Komiyama M, Yatabe Y, Shibata T, Ichikawa H, Ichimura K, Kawai A, Mori T. Identification of novel SSX1 fusions in synovial sarcoma. Mod Pathol 2022; 35: 228-239. https://doi.org/10.1038/s41379-021-00910-x